Clinical development failure for nimacimab
The company’s value is concentrated in a single lead program and clinical outcomes are uncertain.
- Scope
- Lead obesity program
- Materiality
- high
Skye Bioscience, Inc.
Skye Bioscience, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing GPCR-modulating therapies for obesity, overweight, and related conditions. Its lead program, nimacimab, is a subcutaneous injectable antibody targeting the CB1 receptor, and the company operates through a small corporate structure with subsidiaries in the United States, Australia, and Canada.
3.30
3.30
| % | |
|---|---|
| Lead clinical program | 100% Development of nimacimab, a CB1-targeting antibody for obesity and related metabolic conditions. |
| Discovery and preclinical pipeline | 0% Early-stage research on additional GPCR-modulating molecules and related assets. |
| Clinical development services | 0% Use of CROs, investigative sites, and consultants to run trials and support regulatory advancement. |
| Manufacturing and CMC development | 0% Third-party manufacturing and process development for nimacimab and future biologics. |
Skye Bioscience does not yet commercialize products, so its near-term counterparties are primarily clinical trial...
- Clinical research partnersprimary
CROs, investigators, and trial sites that execute nimacimab studies and generate clinical data.
- Manufacturing partnersprimary
Third-party biologics manufacturers and consultants that support drug substance and drug product supply.
- Future prescribers and care providerssecondary
Physicians and obesity-treatment providers who would prescribe nimacimab if approved.
- Potential collaboration partnerssecondary
Pharmaceutical or biotech partners that may provide funding, development support, or commercialization reach.
Skye Bioscience is headquartered in San Diego, California and also maintains administrative office space in San...
- •Headquartered in San Diego, California
- •Administrative office space in San Francisco, California
- •Subsidiaries in the United States, Australia, and Canada
- •Clinical and manufacturing work is outsourced across partner locations
- •No disclosed revenue by country because the company has no revenue
Skye Bioscience’s strategy centers on advancing nimacimab through clinical development and building evidence for its...
01
Advance nimacimab through clinical trialsshort-term
Clinical proof-of-concept is the main value driver for a pre-commercial biotech.
02
Secure manufacturing and development partnersshort-term
The company depends on external providers for clinical supply and trial execution.
03
Expand the GPCR-based pipelinemedium-term
A broader pipeline can diversify scientific risk beyond a single lead asset.
04
Prepare for future commercialization or partneringmedium-term
Approval would require sales, distribution, and market access capabilities.
Skye Bioscience faces the typical risks of a clinical-stage biotech: uncertain trial outcomes, dependence on external...
Dependence on third-party manufacturers and CROs
Skye lacks internal commercial and manufacturing infrastructure, creating execution and supply risk.
- Scope
- Clinical supply and trial operations
- Materiality
- high
Need for additional financing
Development-stage biotech programs consume cash before any product revenue is generated.
- Scope
- Operating runway and trial funding
- Materiality
- high
Competition from larger biopharma companies
Competitors may have more resources, broader pipelines, and faster development capabilities.
- Scope
- Obesity and metabolic disease
- Materiality
- medium
Intellectual property protection
The company’s ability to defend its proprietary molecules and methods affects long-term value.
- Scope
- Nimacimab and GPCR platform
- Materiality
- medium
Accrued research and development expenses
Can shift expense recognition between quarters
Fair value of acquired assets
Can influence intangible asset balances and future impairment risk
Legal contingencies
May create one-time gains, losses, or reserve changes
Stock-based compensation
Affects reported G&A and R&D costs
Spyre Therapeutics, Inc.
SYRE · Pharmaceutical Preparations
Spyre Therapeutics is a U.S.-based clinical-stage biotechnology company focused on developing long-acting antibody therapies for inflammatory bowel disease and rheumatic diseases.
SOLIGENIX, INC.
SNGX · Pharmaceutical Preparations
ProPhase Labs, Inc.
PRPH · Pharmaceutical Preparations
SCYNEXIS INC
SCYX · Pharmaceutical Preparations
DYADIC INTERNATIONAL INC
DYAI · Biological Products, (No Diagnostic Substances)
Dyadic International is a U.S.-based biotechnology platform company that develops microbial protein production systems for industrial, life sciences, food and…
Ensysce Biosciences, Inc.
ENSC · Pharmaceutical Preparations
: 29.4.2026